I

IBEX

Biotech company: antibodies and gene therapy

Fraud and Risk Agent

Full-TimeUpdated on 10/15/2026Deadline 12/30/26
No salary listed
Entry
Islamabad, Islamabad Capital Territory, Pakistan
In Person
Risk & ComplianceFinancial Crime & AML

About the job

Requirements
  • 0–1 years of experience in fraud detection, risk management, payments, or a related field.
  • Strong analytical and investigative skills, with attention to detail.
  • Familiarity with fraud detection tools or internal case management systems such as Salesforce.
  • Understanding of regulatory requirements such as Know Your Customer and Anti-Money Laundering.
  • Ability to work flexible hours, including weekends or holidays when needed.
Responsibilities
  • Monitor real-time transactions for suspicious or high-risk activity using internal and third-party tools.
  • Investigate potential fraud, account takeovers, identity theft, chargebacks, and other suspicious activity.
  • Analyze fraud trends and contribute to developing rules and strategies to prevent financial loss.
  • Escalate complex or high-impact cases to senior risk analysts or internal teams.
  • Collaborate with customer support, compliance, engineering, and legal teams to improve processes and reduce fraud.
  • Prepare accurate and timely reports on fraud incidents, resolutions, and risk trends.
  • Maintain current knowledge of fraud typologies, regulations such as Know Your Customer and Anti-Money Laundering, and industry best practices.
  • Respond to requests from payment processors or financial institutions related to fraud or disputes.
  • Recommend improvements to policies, workflows, and automation tools.

About the company

Ibex Biosciences focuses on discovering, validating, and producing biotechnology solutions for health and ecological challenges. Its product portfolio includes therapeutic antibodies, gene therapy, and stem cell programs, as well as diagnostic antibodies for Immunohistochemistry (IHC) to improve biopsy accuracy. The company advances its products by conducting exploratory R&D on projects that may not yet be validated in public research, then develops and commercializes these technologies through licensing, partnerships, and direct sales to healthcare and research institutions. A key differentiator is Ibex’s diversified, internally driven pipeline and its mix of therapeutics and diagnostics, alongside active engagement in grant funding and patenting. The company’s goal is to bring proprietary biotech innovations to market to enhance patient outcomes and health-related research, addressing significant cancer-related and other health challenges.

Company Size

1-10

Company Stage

Early VC

Total Funding

$4.2M

Headquarters

North Bethesda, Maryland

Founded

2015

Get referred to IBEX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ibex keeps an open 506(c) offering, signaling active capital formation in 2026.
  • The 2022 CD147 patent supports oncology and inflammation licensing conversations.
  • Anti-MIF VHH development continues, with animal-model testing already disclosed.

What critics are saying

  • Ibex has no disclosed commercial products, leaving revenue dependent on financing.
  • The open Regulation D offering implies dilution risk and financing pressure through 2026.
  • Without clinical validation, the company risks becoming a perpetual patent shop.

What makes IBEX unique

  • North Bethesda-based Ibex Biosciences focuses on antibody, gene-therapy, and stem-cell programs.
  • Its 2026 pipeline spans CD147 antibodies, anti-MIF VHHs, and PCBP1 stem-cell methods.
  • Ibex still controls early patentable assets, including 2022 CD147 publication.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Ibex Innovations
Mar 12th, 2025
IBEX Completes £2m Fundraise for Osteoporosis

IBEX has successfully completed a £2 million funding round to advance its mission of using X-ray technology to diagnose osteoporosis early. The company aims to shift from reactive to proactive treatment of this silent disease. With partnerships established with X-ray and mammography OEMs in 2024, IBEX plans to deploy its technology in clinical settings by 2025, demonstrating cost savings for the NHS.

Globes
Feb 8th, 2022
Gauzy acquires Vision Systems

Israeli light control nanotech and smart glass company Gauzy has announced that it has acquired French company Vision Systems, which develops ADAS (Advanced Driver Assistance System) and shading solutions for the aeronautic, land transport, and marine industries.